Tags

Type your tag names separated by a space and hit enter

Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents.
Paediatr Drugs 2012; 14(2):91-108PD

Abstract

Adolescent smoking remains a public health problem. Despite concerns regarding adolescent nicotine dependence, few well-designed smoking cessation studies have been conducted with teen smokers. This is particularly true regarding pharmacologic treatments for nicotine dependence. Currently, pharmacologic aids are not recommended for treating adolescent nicotine dependence, as efficacy has not been shown in this population. This review includes studies that have examined the efficacy of pharmacotherapy for smoking abstinence and/or reduction in cigarette consumption among adolescent smokers who want to quit smoking, laboratory-based adolescent studies that have examined the efficacy of these medications in reducing cravings and/or withdrawal symptoms, and/or studies that have assessed the tolerability of medications for smoking cessation in adolescent smokers. It provides information on the pharmacologic action of each medication, the efficacy of each medication for adolescent smoking cessation, the tolerability of each medication based on reported adverse events, and compliance with the medication protocols. Thirteen relevant articles were identified and included in the review. Nicotine patch (NP), nicotine gum, nicotine nasal spray, bupropion, and varenicline have been studied in adolescent smokers. The adverse events reported in the studies on pharmacology for adolescent smoking suggest that the side effect profiles for nicotine replacement therapy, bupropion, and varenicline are similar to those reported in adult studies. There is some evidence of efficacy of NP and bupropion at the end of treatment (efficacy of varenicline has not been assessed), but none of the medications included in this review were efficacious in promoting long-term smoking cessation among adolescent smokers. It is noted that many of the study protocols did not follow the recommended dose or length of pharmacotherapy for adults, rendering it difficult to determine the true efficacy of medication for adolescent smoking cessation. Future efficacy studies are warranted before recommending pharmacotherapy for adolescent smoking cessation.

Authors+Show Affiliations

Oregon Health Science University, Department of Family Medicine, Portland, OR 97239, USA. bailstef@ohsu.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

22248234

Citation

Bailey, Steffani R., et al. "Efficacy and Tolerability of Pharmacotherapies to Aid Smoking Cessation in Adolescents." Paediatric Drugs, vol. 14, no. 2, 2012, pp. 91-108.
Bailey SR, Crew EE, Riske EC, et al. Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents. Paediatr Drugs. 2012;14(2):91-108.
Bailey, S. R., Crew, E. E., Riske, E. C., Ammerman, S., Robinson, T. N., & Killen, J. D. (2012). Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents. Paediatric Drugs, 14(2), pp. 91-108. doi:10.2165/11594370-000000000-00000.
Bailey SR, et al. Efficacy and Tolerability of Pharmacotherapies to Aid Smoking Cessation in Adolescents. Paediatr Drugs. 2012 Apr 1;14(2):91-108. PubMed PMID: 22248234.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents. AU - Bailey,Steffani R, AU - Crew,Erin E, AU - Riske,Emily C, AU - Ammerman,Seth, AU - Robinson,Thomas N, AU - Killen,Joel D, PY - 2012/1/18/entrez PY - 2012/1/18/pubmed PY - 2013/3/30/medline SP - 91 EP - 108 JF - Paediatric drugs JO - Paediatr Drugs VL - 14 IS - 2 N2 - Adolescent smoking remains a public health problem. Despite concerns regarding adolescent nicotine dependence, few well-designed smoking cessation studies have been conducted with teen smokers. This is particularly true regarding pharmacologic treatments for nicotine dependence. Currently, pharmacologic aids are not recommended for treating adolescent nicotine dependence, as efficacy has not been shown in this population. This review includes studies that have examined the efficacy of pharmacotherapy for smoking abstinence and/or reduction in cigarette consumption among adolescent smokers who want to quit smoking, laboratory-based adolescent studies that have examined the efficacy of these medications in reducing cravings and/or withdrawal symptoms, and/or studies that have assessed the tolerability of medications for smoking cessation in adolescent smokers. It provides information on the pharmacologic action of each medication, the efficacy of each medication for adolescent smoking cessation, the tolerability of each medication based on reported adverse events, and compliance with the medication protocols. Thirteen relevant articles were identified and included in the review. Nicotine patch (NP), nicotine gum, nicotine nasal spray, bupropion, and varenicline have been studied in adolescent smokers. The adverse events reported in the studies on pharmacology for adolescent smoking suggest that the side effect profiles for nicotine replacement therapy, bupropion, and varenicline are similar to those reported in adult studies. There is some evidence of efficacy of NP and bupropion at the end of treatment (efficacy of varenicline has not been assessed), but none of the medications included in this review were efficacious in promoting long-term smoking cessation among adolescent smokers. It is noted that many of the study protocols did not follow the recommended dose or length of pharmacotherapy for adults, rendering it difficult to determine the true efficacy of medication for adolescent smoking cessation. Future efficacy studies are warranted before recommending pharmacotherapy for adolescent smoking cessation. SN - 1179-2019 UR - https://www.unboundmedicine.com/medline/citation/22248234/Efficacy_and_tolerability_of_pharmacotherapies_to_aid_smoking_cessation_in_adolescents_ L2 - https://dx.doi.org/10.2165/11594370-000000000-00000 DB - PRIME DP - Unbound Medicine ER -